Stockscreener 앱 받기
30.36
1.07%
0.32
시간 외 거래:
30.26
-0.10
-0.33%
Tg Therapeutics Inc 주식(TGTX)의 최신 뉴스
TG Therapeutics (TGTX) Secures $750 Million Credit Facility - GuruFocus
TG Therapeutics secures $750M credit facility with Blue Owl By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) Secures $750M Credit Facility, Expands Sh - GuruFocus
TG Therapeutics Receives $500 Million in New Capital From Blue Owl, Increases Share Buyback - marketscreener.com
TG Therapeutics secures an additional $500 million in non-dilutive capital from Blue Owl and expands share repurchase program to $300 million - marketscreener.com
TG Therapeutics Secures An Additional $500 Million In Non-Dilutive Capital From Blue Owl And Expands Share Repurchase Program To $300 Million - TradingView
TG Therapeutics Secures an Additional $500 Million in - GlobeNewswire
Penn Capital Management Company LLC Grows Stock Position in TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics Analysis: Strong Clinical Data Boost Briumvi Prospects - timothysykes.com
TG Therapeutics (NASDAQ:TGTX) Shares Up 7.9%Here's What Happened - MarketBeat
How BRIUMVI’s Strong High‑Risk MS Data At TG Therapeutics (TGTX) Has Changed Its Investment Story - simplywall.st
TGTX SEC FilingsTg Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
TGTX Q4 earnings lag estimates, Briumvi sales drive top line - MSN
TG Therapeutics to present BRIUMVI data at neurology meeting - Investing.com Nigeria
A Look At TG Therapeutics (TGTX) Valuation After New BRIUMVI Efficacy Data In Relapsing Multiple Sclerosis - simplywall.st
TG Therapeutics Inc (NASDAQ:TGTX) Presents a Compelling Momentum Case with Strong Growth and Technical Setup - ChartMill
TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
(TGTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Briumvi momentum leads to strong execution for TG Therapeutics (TGTX) - MSN
BRIUMVI Momentum Leads to Strong Execution for TG Therapeutics (TGTX) - Yahoo Finance
WINTON GROUP Ltd Buys 113,951 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
TG Therapeutics, Inc.Common Stock (NQ: TGTX - The Chronicle-Journal
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Is TG Therapeutics (TGTX) Pricing Reflecting Its Mixed Multi Year Share Performance? - Yahoo Finance
TGTX: Positive Phase 3 Analysis Results for Briumvi in Treating Multiple Sclerosis - GuruFocus
MS patients on BRIUMVI saw far fewer relapses and brain lesions - Stock Titan
Bank of America Securities bearish on TG Therapeutics (TGTX) post earnings - MSN
Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis - Sahm
How Investors Are Reacting To TG Therapeutics (TGTX) Adding Azer-cel Milestone to Its MS Portfolio - Yahoo Finance
Azer Cel Milestone Broadens TG Therapeutics Autoimmune Pipeline And Valuation Story - Yahoo Finance
Assessing TG Therapeutics (TGTX) Valuation After BRIUMVI‑Led Earnings And Autoimmune Pipeline Updates - Yahoo Finance
Bank of America Securities Bearish on TG Therapeutics (TGTX) Post Earnings - Finviz
TGTX (TG Therapeutics) Total Assets : $1,063.3 Mil (As of Dec. 2025) - GuruFocus
Is TG Therapeutics Inc. (NKB2) stock included in top ETFs2026 Buyback Activity & AI Forecast Swing Trade Picks - Naître et grandir
TG Therapeutics to present BRIUMVI data at neurology meeting By Investing.com - Investing.com Canada
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
TG Therapeutics, Inc. $TGTX Stake Cut by Teachers Retirement System of The State of Kentucky - MarketBeat
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - Bitget
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting - The Manila Times
TG Therapeutics Azer Cel Milestone Adds Depth To Autoimmune Valuation Story - Sahm
Reports Suggest TG Therapeutics May Be Scaling Back Operations Amid Speculation on CafePharma Forum - geneonline.com
TG Therapeutics Q2 EPS Estimate Lowered by HC Wainwright - MarketBeat
TG Therapeutics Q4 EPS Forecast Lowered by HC Wainwright - MarketBeat
Analysts Offer Insights on Healthcare Companies: Astrana Health (ASTH) and TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics Milestone With Azer Cel Adds New Dimension To Growth Story - Sahm
TG Therapeutics Confronts Rising AI Regulatory and IP Risks That Could Pressure Costs, Strategy, and Growth - The Globe and Mail
Precision BioSciences (DTIL) Hits Milestone, Secures $7.5M from TG Therapeutics - GuruFocus
TG Therapeutics, Inc. (TGTX) Growth Potential: Navigating A 47.65% Upside In Biotech - DirectorsTalk Interviews
Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis - Yahoo Finance
HC Wainwright Raises Earnings Estimates for TG Therapeutics - MarketBeat
Is TG Therapeutics’ 2025 Earnings Miss and BRIUMVI Guidance Shift Altering The Investment Case For TGTX? - simplywall.st
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2025 Earnings Call Transcript - Insider Monkey
TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025 - Finviz
TG Therapeutics (TGTX) Earnings Spark Debate As 72.6% Net Margin Defies Forecast Narratives - Sahm
TG Therapeutics Five Year Briumvi Data Highlights Durable Efficacy And Valuation Gap - Sahm
TGTX Q4 Earnings Lag Estimates, Briumvi Sales Drive Top Line - The Globe and Mail
Decoding TG Therapeutics Inc (TGTX): A Strategic SWOT Insight - GuruFocus
TGTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
TG Therapeutics Five Year BRIUMVI Data And What It Means For Valuation - Yahoo Finance
1.20%
0.06%
자본화:
|
볼륨(24시간):